News

All of the shares of common stock were offered and sold by Discovery Labs pursuant to an effective registration statement previously filed with the Securities and Exchange Commission.

Groups treated with R788 at 100mg and 150mg orally, twice daily, showed higher ACR20, ACR50, ACR70 and DAS28 response rates than the placebo group. The efficacy results for

In 2007, Starlims expects to record a total of $1 million in revenue from this customer with the current $800,000 sale covering licenses for Starlims Version 10 software.

The results demonstrated that out of 13 acute myeloid leukemia (AML) patients treated in this study, three showed a complete response and one further AML patient became transfusion-independent;

GSK1160724 is a long-acting muscarinic antagonist (LAMA) discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for

Although VGX-410C was safe and well tolerated in patients in all three daily doses – 150, 300, and 600mg, one out of six patients in the 600mg dose

Accelrys says biological registration systems are inherently more complex than existing chemical registration systems which are commonplace in the pharmaceutical industry. In discussions with pharmaceutical companies, Accelrys has

In September 2007, AngioDynamics and PhotoMedex entered into a three-year OEM agreement under which PhotoMedex manufactures for AngioDynamics, on a non-exclusive basis, a private-label, 980-nanometer diode laser system.

The private placement will consist of 1.72 million shares at a price of $0.58. The closing of this transaction will bring Mr Laurin’s direct and indirect ownership position